20.64USD+0.40%Mkt Cap: 1.43B USDP/E: —Last update: 2026-06-01
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a prote…
Industry Peers
Medical Devices152.01BUSDP/E 24.4
115.59BUSDP/E 34.9
71.08BUSDP/E 20.0
54.41BSEKP/E 101.6
52.05BDKKP/E 22.0
51.03BUSDP/E 47.9
50.55BSEKP/E 21.4
38.34BEURP/E 18.1
Indicators:|
Key Statistics
Company
Market Cap1.43B USD
Enterprise Value1.69B USD
Revenue (TTM)87.16M USD
Gross Profit41.70M USD
Net Income (TTM)-29.82M USD
Revenue/Share7.387 USD
Last Price20.64 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees222
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-29.05
PEG—
EV/EBITDA-52.76
EV/Revenue19.42
P/S16.26
P/B-7.96
EPS (TTM)-0.65
EPS (Forward)-0.70
52W Range
18.8422% of range27.20
52W High27.20 USD
52W Low18.84 USD
Profitability
Gross Margin56.20%
Oper. Margin-47.42%
EBITDA Margin-36.81%
Profit Margin-40.18%
ROE18.76%
ROA-21.30%
Growth
Revenue Growth98.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-53.61M USD
CapEx (TTM)6.38M USD
FCF Margin—
FCF Yield—
Net Debt40.96M USD
Net Debt/EBITDA-1.28
Balance Sheet
Debt/Equity-0.26
Current Ratio5.88
Quick Ratio3.50
Book Value/Sh-2.5690 USD
Cash/Share0.9320 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)30.00 USD
Target Range27.00 USD – 35.00 USD
# Analysts5
Ownership
Shares Out.69.31M
Float38.15M
Insiders26.67%
Institutions28.31%
Short Interest
Short Ratio3.2d
Short % Float3.98%
Short % Out.2.45%
Shares Short1.15M
Technical
SMA 5022.87 (-9.8%)
SMA 20022.87 (-9.8%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)277.88K
Avg Vol (10d)245.63K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—